Due to the continuous strong demand for disinfectants, specialty chemicals company Lanxess plans to expand production capacity for Oxone monopersulfate by around 50%, according to the company. The company reportedly intends to invest a lower double-digit million euro sum in its production facility in Memphis, Tenn.
Lanxess uses Oxone monopersulfate as the main active ingredient in many of its Virkon and Rely+On disinfection products. Demand for these products has increased significantly in recent months due to the outbreak of African swine fever and the coronavirus pandemic, according to the company. Lanxess also sells Oxone, a powerful oxidizing agent, for numerous other applications. The capacity expansion is expected to be completed in the second half of 2022.
Michael Schäfer, head of Lanxess’ material protection products business unit, says, “We are also seeing a growing demand for Oxone in the water treatment sector as well as from the electronics and paper industries. We want to meet this demand by expanding our production capacity.”
Lanxess develops and sells products that agricultural businesses use for disinfection purposes under the umbrella brand Virkon. Lanxess also offers disinfectants for human health: Rely+On Virkon is used in hospitals, laboratories, public institutions and for medical equipment. It can completely inactivate the coronavirus SARS-CoV-2 in 60 seconds, according to the company.
For more information, visit: www.lanxess.com
